When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CYAD - Celyad up 9% on positive data on non-gene edited CAR T therapy
Celyad SA
Ultra-thinly traded micro cap Celyad (CYAD+9.0%) is up on more than double normal volume, albeit on turnover of only 39K shares, in reaction to updated data from a Phase 1 clinical trial, alloSHRINK, evaluating CYAD-101 in patients with metastatic colorectal cancer (mCRC). The results were virtually presented at ASCO.
More news on: Celyad SA, Healthcare stocks news, Stocks on the move,